Preview

Злокачественные опухоли

Расширенный поиск

ХИМИОТЕРАПИЯ У ПОЖИЛЫХ ПАЦИЕНТОВ, СТРАДАЮЩИХ РАКОМ ЖЕЛУДКА

https://doi.org/10.18027/2224-5057-2018-8-2-64-75

Полный текст:

Аннотация

Рак желудка (РЖ) является одним из наиболее частых злокачественных заболеваний, возникающих у пожилых людей. Системная химиотерапия показала улучшение качества жизни и выживаемости по сравнению с паллиативной терапией у пациентов с поздними стадиями РЖ. Также было показано, что пожилые пациенты с РЖ способны переносить и получать эффективную системную химиотерапию, как и более молодые пациенты с той же стадией рака. Возрастной ценз не должен быть единственным критерием для исключения эффективной химиотерапии. Тем не менее правильный отбор пациентов чрезвычайно важен для обеспечения эффективного и безопасного лечения. В статье проанализированы оптимальные режимы химиотерапии с учетом показателей общего состояния и гериатрического функционального статуса пациентов пожилого возраста с РЖ.

Об авторах

О. А. Королева
ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского» (МОНИКИ)
Россия

Ольга А. Королева - ординатор кафедры онкологии и торакальной хирургии



Л. М. Когония
ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского» (МОНИКИ)
Россия

Лали М. Когония - доктор медицинских наук, профессор кафедры онкологии и торакальной хирургии



М. М. Бяхова
ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского» (МОНИКИ)
Россия

Мария М. Бяхова - кандидат медицинских наук, старший научный сотрудник патологоанатомического отделения



А. Г. Титов
ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского» (МОНИКИ); Высоковская городская больница, филиал ГАУЗ МО «Клинская городская больница»; ГАУЗ МО Клинская городская больница
Россия

Андрей Г. Титов - кандидат медицинских наук, ассистент кафедры онкологии и торакальной хирургии Московского областного НИКИ им. М. Ф. Владимирского; зав. онкологического отделения ВГБ, филиал ГАУЗ МО КГБ; руководитель филиала кафедры онкологии в ГАУЗ МО КГБ 



Список литературы

1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015. Vol. 136. P. E359–86.

2. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Lyon, France: International Agency for Research on Cancer, 2013. Available from: http://globocan.iarc.fr.

3. Parkin D. M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer. 2006. Vol. 118. P. 3030–3044.

4. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014. Vol. 64. P. 9–29.

5. Статистика злокачественных новообразований в России и странах СНГ в 2013 г. / под ред. Давыдова М. И., Аксель Е. М. Москва, 2015.

6. Glimelius B., Ekstrom K., Hoffman K., Graf W., Sjoden P. O., Haglund U. et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 1997. Vol. 8. P. 163–168.

7. Pyrhonen S., Kuitunen T., Nyandoto P., Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer. 1995. Vol. 71. P. 587–591.

8. Murad A. M., Santiago F. F., Petroianu A., Rocha P. R., Rodrigues M. A., Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993. Vol. 72. P. 37–41.

9. Polee M. B., Hop W. C., Kok T. C., Eskens F. A., van der Burg M. E., Splinter T. A. et al. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br. J. Cancer. 2003. Vol. 89. P. 2045–2050.

10. Chau I., Norman A. R., Cunningham D., Waters J. S., Oates J., Ross P. J. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J. Clin. Oncol. 2004. Vol. 22. P. 2395–2403.

11. Trumper M., Ross P. J., Cunningham D., Norman A. R., Hawkins R., Seymour M. et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. Eur. J. Cancer. 2006. Vol. 42. P. 827–834.

12. Jatoi A., Foster N. R., Egner J. R., Burch P. A., Stella P. J., Rubin J. et al. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int. J. Oncol. 2010. Vol. 36. P. 601–606.

13. Hurria A., Lichtman S. M. Clinical pharmacology of cancer therapies in older adults. Br. J. Cancer. 2008. Vol. 98. P. 517–522.

14. Repetto L., Fratino L., Audisio R. A., Venturino A., Gianni W., Vercelli M. et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J. Clin. Oncol. 2002. Vol. 20. P. 494–502.

15. Wedding U., Kodding D., Pientka L., Steinmetz H. T., Schmitz S. Physicians’ judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit. Rev. Oncol. Hematol. 2007. Vol. 64. P. 1–9.

16. Extermann M., Aapro M., Bernabei R., Cohen H. J., Droz J. P., Lichtman S. et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit. Rev. Oncol. Hematol. 2005. Vol. 55. P. 241–252.

17. Extermann M., Hurria A. Comprehensive geriatric assessment for older patients with cancer. J. Clin. Oncol. 2007. Vol. 25. P. 1824–1831.

18. Pal S. K., Katheria V., Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J. Clin. 2010. Vol. 60. P. 120–132.

19. Rodin M. B., Mohile S. G. A practical approach to geriatric assessment in oncology. J. Clin. Oncol. 2007. Vol. 25. P. 1936–1944.

20. Hurria A., Gupta S., Zauderer M., Zuckerman E. L., Cohen H. J., Muss H. et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005. Vol. 104. P. 1998–2005.

21. Hurria A., Cirrincione C. T., Muss H. B., Kornblith A. B., Barry W., Artz A. S. et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J. Clin. Oncol. 2011. Vol. 29. P. 1290–1296.

22. Hurria A., Togawa K., Mohile S. G., Owusu C., Klepin H. D., Gross C. P. et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J. Clin. Oncol. 2011. Vol. 29. P. 3457–3465.

23. Cunningham D., Allum W. H., Stenning S. P., Thompson J. N., Van de Velde C. J., Nicolson M. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006. Vol. 355. P. 11–20.

24. Ychou M., Boige V., Pignon J. P., Conroy T., Bouche O., Lebreton G. et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol. 2011. Vol. 29. P. 1715–1721.

25. Xiong B. H., Cheng Y., Ma L., Zhang C. Q. An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer. Cancer Invest. 2014. Vol. 32. P. 272–284.

26. Kulig J., Kolodziejczyk P., Sierzega M., Bobrzynski L., Jedrys J., Popiela T. et al. Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology. 2010. Vol. 78. P. 54–61.

27. Bouche O., Ychou M., Burtin P., Bedenne L., Ducreux M., Lebreton G. et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann. Oncol. 2005. Vol. 16. P. 1488–1497.

28. Sakuramoto S., Sasako M., Yamaguchi T., Kinoshita T., Fujii M., Nashimoto A. et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 2007. Vol. 357. P. 1810–1820.

29. Bang Y. J., Kim Y. W., Yang H. K., Chung H. C., Park Y. K., Lee K. H. et al. CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012. Vol. 379. P. 315–321.

30. Sasako M., Sakuramoto S., Katai H., Kinoshita T., Furukawa H., Yamaguchi T. et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. 2011. Vol. 29. P. 4387–4393.

31. Noh S. H., Park S. R., Yang H. K., Chung H. C., Chung I. J., Kim S. W. et al. CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomized phase 3 trial. Lancet Oncol. 2014. Vol. 15. P. 1389–1396.

32. Wagner A. D., Unverzagt S., Grothe W., Kleber G., Grothey A., Haerting J., Fleig W. E. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 2010. CD004064.

33. Webb A., Cunningham D., Scarffe J. H., Harper P., Norman A., Joffe J. K. et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 1997. Vol. 5. P. 261–267.

34. Kim N. K., Park Y. S., Heo D. S., Suh C., Kim S. Y., Park K. C. et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993. Vol. 71. P. 3813–3818.

35. Ohtsu A., Shimada Y., Shirao K., Boku N., Hyodo I., Saito H. et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol. 2003. Vol. 21. P. 54–59.

36. Lord S. R., Hall P. S., McShane P., Brown J., Seymour M. T. Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy. Clin. Oncol. 2010. Vol. 22. P. 107–113.

37. Cunningham D., Starling N., Rao S., Iveson T., Nicolson M., Coxon F. et al. Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 2008. Vol. 358. P. 36–46.

38. Al-Batran S. E., Hartmann J. T., Probst S., Schmalenberg H., Hollerbach S., Hofheinz R. et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol. 2008. Vol. 26. P. 1435–1442.

39. Santini D., Graziano F., Catalano V., Di Seri M., Testa E., Baldelli A. M. et al. Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. BMC Cancer. 2006. Vol. 6. P. 125–131.

40. Choi I. S., Oh D. Y., Kim B. S., Lee K. W., Kim J. H., Lee J. S. Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer. Cancer Res. Treat. 2007. Vol. 39. P. 99–103.

41. Liu Z. F., Guo Q. S., Zhang X. Q., Yang X. G., Guan F., Fu Z., Wang M. Y. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am. J. Clin. Oncol. 2008. Vol. 31. P. 259–263.

42. Dong N., Jiang W., Li H., Liu Z., Xu X., Wang M. Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer. Am. J. Clin. Oncol. 2009. Vol. 32. P. 559–563.

43. Zhao J. G., Qiu F., Xiong J. P., Zhang L., Xiang X. J., Yu F. et al. A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer. Anticancer Drugs. 2009. Vol. 20. P. 281–286.

44. Xiang X. J., Zhang L., Qiu F., Yu F., Zhan Z. Y., Feng M. et al. A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer. Chemotherapy. 2012. Vol. 58. P. 1–7.

45. Catalano V., Bisonni R., Graziano F., Giordani P., Alessandroni P., Baldelli A. M. et al. A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer. 2013. Vol. 16. P. 411–419.

46. Nardi M., Azzarello D., Maisano R., Del Medico P., Giannicola R., Raffaele M. et al. FOLFOX-4 regimen as fist-line chemotherapy in elderly patients with advanced gastric cancer: a safety study. J. Chemother. 2007. Vol. 19. P. 85–89.

47. Kim H. S., Kim J. H., Kim H. J., Jang H. J., Kim J. B., Kim J. W. et al. Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status. Oncol. Lett. 2012. Vol. 3. P. 425–428.

48. Cho Y. H., Kim S. Y., Hong Lee M., Yoo M. W., Bang H. Y., Lee K. Y., Yoon S. Y. Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil / leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer. Gastric Cancer. 2012. Vol. 15. P. 389–395.

49. Al-Batran S. E., Pauligk C., Homann N., Hartmann J. T., Moehler M., Probst S. et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur. J. Cancer. 2013. Vol. 49. P. 835–842.

50. Kang Y. K., Kang W. K., Shin D. B., Chen J., Xiong J., Wang J. et al. Capecitabine / cisplatin versus 5-fluorouracil / cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann. Oncol. 2009. Vol. 20. P. 666–673.

51. Okines A. F., Norman A. R., McCloud P., Kang Y. K., Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann. Oncol. 2009. Vol. 20. P. 1529–1534.

52. Boku N., Yamamoto S., Fukuda H., Shirao K., Doi T., Sawaki A. et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009. Vol. 10. P. 1063–1069.

53. Ajani J. A., Rodriguez W., Bodoky G., Moiseyenko V., Lichinitser M., Gorbunova V. et al. Multicenter phase III comparison of cisplatin / S-1 with cisplatin / infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J. Clin. Oncol. 2010. Vol. 28. P. 1547–1553.

54. Lee J. L., Kang Y. K., Kang H. J., Lee K. H., Zang D. Y., Ryoo B. Y. et al. A randomized multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br. J. Cancer. 2008. Vol. 99. P. 584–590

55. Hwang I. G., Lee H. R., Lee H. Y., Ji J. H., Kang J. H., Lee S. I. et al. First-line capecitabine (X) monotherapy versus capecitabine plus oxaliplatin (XELOX) in elderly patients with advanced gastric cancer (AGC): results from the first interim analysis. J. Clin. Oncol. 2015. Vol. 33 (suppl). abstr4051.

56. Koizumi W., Akiya T., Sato A., Sakuyama T., Sasaki E., Tomidokoro T. et al. Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study. Cancer Chemother. Pharmacol. 2010. Vol. 65. P. 1093–1099.

57. Petrioli R., Pascucci A., Francini E., Marsili S., Fiaschi A. I., Civitelli S. et al. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. Anticancer Drugs. 2008. Vol. 19. P. 91–96.

58. Bang Y. J., Van Cutsem E., Feyereislova A., Chung H. C., Shen L., Sawaki A. et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010. Vol. 376. P. 687–697.

59. Fuchs C. S., Tomasek J., Yong C. J., Dumitru F., Passalacqua R., Goswami C. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet. 2014. Vol. 383. P. 31–39.

60. Wilke H., Muro K., Van Cutsem E., Oh S. C., Bodoky G., Shimada Y. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014. Vol. 15. P. 1224–1235.

61. Van Cutsem E., Moiseyenko V. M., Tjulandin S. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 2006. Vol. 24. P. 4991–4997.

62. Ajani J. A., Moiseyenko V. M., Tjulandin S. et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J. Clin. Oncol. 2007. Vol. 25. P. 3210–3216.

63. Ilson D. H. Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J. Clin. Oncol. 2007. Vol. 25 (22). P. 3188–3190.

64. Cunningham D., Starling N., Rao S. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 2008. Vol. 358 (1). P. 36–46.


Для цитирования:


Королева О.А., Когония Л.М., Бяхова М.М., Титов А.Г. ХИМИОТЕРАПИЯ У ПОЖИЛЫХ ПАЦИЕНТОВ, СТРАДАЮЩИХ РАКОМ ЖЕЛУДКА. Злокачественные опухоли. 2018;8(2):64-75. https://doi.org/10.18027/2224-5057-2018-8-2-64-75

For citation:


Koroleva O.A., Kogoniya L.M., Byakhova M.M., Titov A.G. CHEMOTHERAPY IN ELDERLY PATIENTS WITH STOMACH CANCER. Malignant tumours. 2018;8(2):64-75. (In Russ.) https://doi.org/10.18027/2224-5057-2018-8-2-64-75

Просмотров: 355


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)